From Data to Decisions: Evolving Opportunities in Platinum Resistant Ovarian Cancer
Industry Supported Symposium

Activity Overview

The GOG Foundation, Inc. and GOG Partners welcomes gynecologic oncologists, oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with gynecologic malignancies to attend the From Data to Decisions: Evolving Opportunities in Platinum Resistant Ovarian Cancer Industry Supported Symposium being held in-person at the IGCS 2025 Annual Global Meeting in Cape Town, South Africa on Friday, November 7, 2025 from 12:40 – 14:10 GMT+2.

While antibody-drug conjugates (ADCs) have reshaped therapeutic paradigms, the latest clinical trial results reveal a broader array of opportunities, spanning novel mechanisms of action, immunotherapy-based combinations, and molecularly targeted strategies. Through rigorous analysis of newly presented efficacy and safety data, including key PFS/OS endpoints, expert faculty will provide context and interpretation to support real-world clinical decisions. Interactive discussion will center on how these innovations are poised to reshape treatment sequencing and improve patient outcomes. This dynamic symposium will spotlight the most compelling new data presented at 2025 oncology congresses, including ASCO, ESMO GYN, and ESMO—focusing on evolving strategies for the management of advanced, platinum-resistant high-grade epithelial ovarian cancer.

This educational activity is supported by an independent medical education grant from Corcept Therapeutics, Inc.

Target Audience

Gynecologic and medical oncologists, oncology researchers, clinical trial investigators, advanced practice providers, and healthcare professionals involved in the care of patients with ovarian cancer.

Learning Objectives

Upon completion of the activities in this series, learners will demonstrate Increased knowledge regarding:

  • Evaluate Breakthrough Data: Review and contextualize pivotal 2025 congress data on novel therapies in platinum-resistant ovarian cancer.
  • Interpret Clinical Impact of New Trials: Analyze updated PFS/OS findings, trial design nuances, and their practical implications for personalized treatment planning.
  • Map the Evolving Therapeutic Landscape: Position emerging treatments within the current ovarian cancer algorithm, identifying opportunities for sequencing or combination.
  • Enhance Multidisciplinary Application: Foster real-world clinical dialogue among oncology professionals to translate data into meaningful care strategies.

Agenda

From Data to Decisions: Evolving Opportunities in Platinum Resistant Ovarian Cancer, an Industry Supported Symposium at the IGCS 2025 Annual Global Meeting

This session is not included in the main event CME/CPD credit.

In Person on Friday, November 7, 2025 from 12:40 – 14:10 GMT+2 in Cape Town, South Africa

12:40 – 12:45 GMT+2
Welcome & Framing the Discussion
Debra Richardson, MD; University of Oklahoma, Stephenson Cancer Center, Oklahoma City, Oklahoma, USA
12:45 – 13:00 GMT+2
What’s New in Platinum-Resistant Ovarian Cancer: Highlights from ASCO, ESMO GYN, and ESMO 2025
Nicoletta Colombo, MD, PhD; European Institute of Oncology and Univesrity of Milan-Bicocca, Milan, Italy
13:00 – 13:15 GMT+2
Innovative Mechanisms and Combinations: Beyond ADCs in 2025
Domenica Lorusso, MD, PhD, Humanitas Hospital San Pio X Humanitas University, Rozzano, Milan, Italy
13:15 – 13:30 GMT+2
Making Sense of the Curves: How to Interpret New PFS/OS Data
David O’Malley, MD, The Ohio State University, Comprehensive Cancer Center, Columbus, Ohio, USA
13:30 – 13:55 GMT+2
Faculty Panel: Treatment Integration and What’s Next
All Faculty
13:55 – 14:05 GMT+2
Audience Q&A
All Faculty
14:05 – 14:10 GMT+2
Closing Remarks
Debra Richardson, MD; University of Oklahoma, Stephenson Cancer Center, Oklahoma City, Oklahoma, USA